Tag: Bayer
Patients with multiple revascularisations are at higher risk of acute limb...
Symptomatic peripheral arterial disease (PAD) patients undergoing recurrent lower extremity revascularisation have higher rates of ischaemic events, particularly acute limb ischaemia, than those patients...
Xarelto (rivaroxaban) reduces risk of major amputation by 70% in peripheral...
Bayer and its cooperation partner Janssen Research & Development have announced two publications of further data from the Phase III COMPASS study in The...
ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and...
The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...
